Macquarie Group’s INmune Bio INMB Stock Holding History

Macquarie Group’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-444	Closed	-$5	–	2006
2024 Q1	$5	Buy	+444	New	+$5.36K	﹤0.01%	1786

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Praetorian PR Rincon, Puerto Rico $275M AUM 84.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Macquarie Group's INMB Position: Q2 2024 in Review

Macquarie Group sold out of INmune Bio (INMB) in Q2 2024, closing a stake of 444 shares — an estimated $5 sold.

Macquarie Group first reported a position in INMB in Q1 2024 and held it in 1 quarter. The position peaked at $5 in Q1 2024. 57 funds tracked by Wall St. Rank hold INMB as of Q2 2024.

Macquarie Group reported no remaining INmune Bio position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 444 INmune Bio shares in Q2 2024, an estimated $5.
Macquarie Group first reported a position in INmune Bio in Q1 2024 and held it in 1 quarter.
Macquarie Group's INmune Bio position peaked at $5 in Q1 2024.
57 funds tracked by Wall St. Rank held INmune Bio as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.